Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
303 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03872401 | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke(VESALIUS-CV) | completed | Phase 3 | 12,301 | AmgenINDUSTRY | 33 | Jun 25, 2026 | clinicaltrials |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | recruiting | Phase 3 | 400 | Ascentage Pharma Group Inc.INDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects(CANOPY-1) | terminated | Phase 3 | 673 | Novartis PharmaceuticalsINDUSTRY | 41 | Jun 17, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT04607421 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 841 | PfizerINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT04729387 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | terminated | Phase 3 | 358 | Novartis PharmaceuticalsINDUSTRY | 26 | Jun 4, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT06760637 | Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease(FourLight-3) | active not recruiting | Phase 3 | 1,035 | PfizerINDUSTRY | 30 | May 19, 2026 | clinicaltrials |
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 789 | Regeneron PharmaceuticalsINDUSTRY | 18 | May 18, 2026 | clinicaltrials |
| NCT03819101 | Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer(PEACE-4) | recruiting | Phase 3 | 1,210 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | May 6, 2026 | clinicaltrials |
| NCT04043494 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma(LBL 2018) | recruiting | Phase 3 | 683 | University Hospital MuensterOTHER | 21 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT04916613 | ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)(GETUG-AFU 40) | recruiting | Phase 3 | 300 | UNICANCEROTHER | 12 | Apr 28, 2026 | clinicaltrials |
| NCT05888493 | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma(LEDA) | active not recruiting | Phase 3 | 109 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 17, 2026 | clinicaltrials |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-03) | active not recruiting | Phase 3 | 623 | Gilead SciencesINDUSTRY | 30 | Apr 6, 2026 | clinicaltrials |
| NCT05514054 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer(EMBER-4) | active not recruiting | Phase 3 | 8,000 | Eli Lilly and CompanyINDUSTRY | 31 | Apr 2, 2026 | clinicaltrials |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients(frontMIND) | active not recruiting | Phase 3 | 899 | Incyte CorporationINDUSTRY | 29 | Apr 1, 2026 | clinicaltrials |
| NCT02684708 | Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents | completed | Phase 3 | 2,921 | University of GiessenOTHER | 19 | Mar 31, 2026 | clinicaltrials |
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer(VERITAC-2) | active not recruiting | Phase 3 | 624 | PfizerINDUSTRY | 31 | Mar 18, 2026 | clinicaltrials |
| NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) | not yet recruiting | Phase 3 | 750 | Charite University, Berlin, GermanyOTHER | 20 | Mar 17, 2026 | clinicaltrials |
| NCT01602380 | A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.(FALCON) | completed | Phase 3 | 462 | AstraZenecaINDUSTRY | 20 | Feb 27, 2026 | clinicaltrials |
| NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma(COLUMBUS) | completed | Phase 3 | 921 | PfizerINDUSTRY | 29 | Feb 27, 2026 | clinicaltrials |
| NCT00699751 | A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases(ALSYMPCA) | completed | Phase 3 | 921 | BayerINDUSTRY | 19 | Feb 23, 2026 | clinicaltrials |
| NCT05909397 | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer(VERITAC-3) | active not recruiting | Phase 3 | 59 | PfizerINDUSTRY | 10 | Feb 10, 2026 | clinicaltrials |
| NCT02246621 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer(MONARCH 3) | active not recruiting | Phase 3 | 493 | Eli Lilly and CompanyINDUSTRY | 22 | Feb 3, 2026 | clinicaltrials |
| NCT02003924 | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer(PROSPER) | completed | Phase 3 | 1,401 | PfizerINDUSTRY | 32 | Jan 27, 2026 | clinicaltrials |
| NCT03869892 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.(SOLSTICE) | active not recruiting | Phase 3 | 856 | Institut de Recherches Internationales ServierOTHER | 25 | Dec 22, 2025 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT02677896 | A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)(ARCHES) | completed | Phase 3 | 1,150 | Astellas Pharma Global Development, Inc.INDUSTRY | 24 | Oct 24, 2025 | clinicaltrials |
| NCT02367040 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-3) | completed | Phase 3 | 458 | BayerINDUSTRY | 37 | Oct 14, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT00005584 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | active not recruiting | Phase 3 | 1,649 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Aug 5, 2025 | clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT00981058 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin(SQUIRE) | completed | Phase 3 | 1,093 | Eli Lilly and CompanyINDUSTRY | 26 | Jun 18, 2025 | clinicaltrials |
| NCT03390686 | A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients | active not recruiting | Phase 3 | 650 | Prestige Biopharma LimitedINDUSTRY | 17 | May 31, 2025 | clinicaltrials |
| NCT03551626 | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes(COMBI-APlus) | completed | Phase 3 | 552 | Novartis PharmaceuticalsINDUSTRY | 23 | Apr 29, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT03643276 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | recruiting | Phase 3 | 5,000 | Martin SchrappeOTHER | 8 | Apr 6, 2025 | clinicaltrials |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 | Mar 21, 2025 | clinicaltrials |
| NCT00353496 | Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours(CLARINET) | completed | Phase 3 | 264 | IpsenINDUSTRY | 15 | Mar 5, 2025 | clinicaltrials |
| NCT03358875 | Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)(RATIONALE-303) | completed | Phase 3 | 805 | BeiGeneINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT00104676 | Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors | completed | Phase 3 | 263 | UNICANCEROTHER | 3 | Feb 6, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | completed | Phase 3 | 1,214 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 42 | Jan 31, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL(AMPLIFY) | active not recruiting | Phase 3 | 984 | Acerta Pharma BVINDUSTRY | 27 | Dec 27, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials